Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications
Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumou...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2021-11, Vol.911, p.174546, Article 174546 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 174546 |
container_title | European journal of pharmacology |
container_volume | 911 |
creator | Rizvi, Asim Merlin, Marine A. Shah, Girish M. |
description | Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account. |
doi_str_mv | 10.1016/j.ejphar.2021.174546 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2579088619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299921007020</els_id><sourcerecordid>2579088619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</originalsourceid><addsrcrecordid>eNp9kEtr3DAURkVoSaZJ_kEIWk4WnkqyLFlZFIb0CYGY0K6FHncYDX5F0hQC_fGxcdLuutJFOve7ugehK0o2lFDx8bCBw7g3ccMIoxsqecXFCVrRWqqCSMreoRUhlBdMKXWGPqR0IIRUilWn6KzkghBF5Ar9aYb2Ga-3n5siBjskuMHjdNNBNAnwutk-Njc49PtgQw5DP5XYmd5BvMXNkKHPwbQ4dKNx-d8bThk67KBtEza9x3k_xY1wzMHNbBucmcPSBXq_M22Cy9fzHP36-uXn3ffi_uHbj7vtfeFKwXLBrbIOiN3xWkihhOTM1M57CdI7qyRwxpxUlfSs9MIKwoUzu7ICClBJq8pztF5yxzg8HSFl3YU0f8_0MByTZpVUpK4FnVG-oC4OKUXY6TGGzsRnTYmeveuDXrzr2btevE9t168TjrYD_7fpTfQEfFoAmPb8HSDq5AJMsnyI4LL2Q_j_hBcJYJaO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579088619</pqid></control><display><type>article</type><title>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Rizvi, Asim ; Merlin, Marine A. ; Shah, Girish M.</creator><creatorcontrib>Rizvi, Asim ; Merlin, Marine A. ; Shah, Girish M.</creatorcontrib><description>Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account.</description><identifier>ISSN: 0014-2999</identifier><identifier>ISSN: 1879-0712</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2021.174546</identifier><identifier>PMID: 34600907</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cancer stem cells ; Cancer therapy ; Cell death ; Differentiation ; Humans ; Neoplasms - drug therapy ; Neoplasms - pathology ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - pathology ; PARP ; PARP-Inhibitors (PARPi) ; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use ; Poly(ADP-ribose) Polymerases - metabolism</subject><ispartof>European journal of pharmacology, 2021-11, Vol.911, p.174546, Article 174546</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</citedby><cites>FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2021.174546$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27925,27926,45996</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34600907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rizvi, Asim</creatorcontrib><creatorcontrib>Merlin, Marine A.</creatorcontrib><creatorcontrib>Shah, Girish M.</creatorcontrib><title>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer stem cells</subject><subject>Cancer therapy</subject><subject>Cell death</subject><subject>Differentiation</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - pathology</subject><subject>PARP</subject><subject>PARP-Inhibitors (PARPi)</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors - pharmacology</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</subject><subject>Poly(ADP-ribose) Polymerases - metabolism</subject><issn>0014-2999</issn><issn>1879-0712</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtr3DAURkVoSaZJ_kEIWk4WnkqyLFlZFIb0CYGY0K6FHncYDX5F0hQC_fGxcdLuutJFOve7ugehK0o2lFDx8bCBw7g3ccMIoxsqecXFCVrRWqqCSMreoRUhlBdMKXWGPqR0IIRUilWn6KzkghBF5Ar9aYb2Ga-3n5siBjskuMHjdNNBNAnwutk-Njc49PtgQw5DP5XYmd5BvMXNkKHPwbQ4dKNx-d8bThk67KBtEza9x3k_xY1wzMHNbBucmcPSBXq_M22Cy9fzHP36-uXn3ffi_uHbj7vtfeFKwXLBrbIOiN3xWkihhOTM1M57CdI7qyRwxpxUlfSs9MIKwoUzu7ICClBJq8pztF5yxzg8HSFl3YU0f8_0MByTZpVUpK4FnVG-oC4OKUXY6TGGzsRnTYmeveuDXrzr2btevE9t168TjrYD_7fpTfQEfFoAmPb8HSDq5AJMsnyI4LL2Q_j_hBcJYJaO</recordid><startdate>20211115</startdate><enddate>20211115</enddate><creator>Rizvi, Asim</creator><creator>Merlin, Marine A.</creator><creator>Shah, Girish M.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20211115</creationdate><title>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</title><author>Rizvi, Asim ; Merlin, Marine A. ; Shah, Girish M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-4b9bce0bf4867696742a8cdd7e7dcb97e422c7957d23d6b6046caf35e1ee57b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer stem cells</topic><topic>Cancer therapy</topic><topic>Cell death</topic><topic>Differentiation</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - pathology</topic><topic>PARP</topic><topic>PARP-Inhibitors (PARPi)</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors - pharmacology</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</topic><topic>Poly(ADP-ribose) Polymerases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rizvi, Asim</creatorcontrib><creatorcontrib>Merlin, Marine A.</creatorcontrib><creatorcontrib>Shah, Girish M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rizvi, Asim</au><au>Merlin, Marine A.</au><au>Shah, Girish M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2021-11-15</date><risdate>2021</risdate><volume>911</volume><spage>174546</spage><pages>174546-</pages><artnum>174546</artnum><issn>0014-2999</issn><issn>1879-0712</issn><eissn>1879-0712</eissn><abstract>Inhibitors of poly(ADP-ribose) polymerase (PARP) are used in mono- or combination therapies for several malignancies. They are also used as maintenance therapy for some cancers after initial treatment. While the focus of this therapeutic approach is on the effect of PARP inhibition on the bulk tumour cells, in this review, we discuss their effect on the cancer stem cells. We identify key mediators and pathways in cancer stem cells whose response to PARP inhibition is not necessarily the same as the rest of the tumour cells. Since the cancer stem cells are known drivers of growth of tumours and their resistance to therapy, the clinical outcome might be drastically different than what is expected, if the effect of PARP inhibition on the cancer stem cells is not taken into account.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34600907</pmid><doi>10.1016/j.ejphar.2021.174546</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2021-11, Vol.911, p.174546, Article 174546 |
issn | 0014-2999 1879-0712 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_2579088619 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer stem cells Cancer therapy Cell death Differentiation Humans Neoplasms - drug therapy Neoplasms - pathology Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - pathology PARP PARP-Inhibitors (PARPi) Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Poly(ADP-ribose) Polymerases - metabolism |
title | Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T13%3A59%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poly%20(ADP-ribose)%20polymerase%20(PARP)%20inhibition%20in%20cancer:%20Potential%20impact%20in%20cancer%20stem%20cells%20and%20therapeutic%20implications&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Rizvi,%20Asim&rft.date=2021-11-15&rft.volume=911&rft.spage=174546&rft.pages=174546-&rft.artnum=174546&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2021.174546&rft_dat=%3Cproquest_cross%3E2579088619%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579088619&rft_id=info:pmid/34600907&rft_els_id=S0014299921007020&rfr_iscdi=true |